** Medical device maker Nevro Corp's shares rise 18.6% to $6.31 premarket
** On Monday, co posted Q3 revenue of $96.9 mln vs analysts' est. of $93.1 mln - data compiled by LSEG
** Co reported Q3 loss per share of 41 cents vs est. for loss of 81 cents per share
** Expects 2024 adj. EBITDA loss of $16 mln to $18 mln, smaller than earlier forecast for loss of $18 mln to $20 mln
** As of last close, stock had fallen ~75% YTD, as NVRO has struggled with weak demand for some of its products and had earlier cut its revenue forecast
** J.P. Morgan says Nevro's management expects outlook to improve in 2025, but brokerage views Nevro as "a 'show me' story" as it tries to reach breakeven
** Twelve of 16 brokerages rate the stock "hold" and 4 "sell" or lower; median PT is $6.50 - LSEG data
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.